A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is: \- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT? Participants will: * Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks * Visit the clinic every two to four weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib

NCT Number	NCT06868381
Lead Sponsor	Stanford University Collaborators: Eli Lilly and Company
Conditions	Cardiac Sarcoidosis
Enrollment	10 participants
Start Date	2026-04-01
Primary Completion	2028-07-01 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-10